Literature DB >> 1501414

Hydrated clearance of gadolinium-DTPA as a measurement of glomerular filtration rate.

P L Choyke1, H A Austin, J A Frank, M E Girton, R L Diggs, A J Dwyer, L Miller, R Nussenblatt, H McFarland, T Simon.   

Abstract

Technetium (99mTc)-diethylene triamine pentaacetic acid (DTPA) hydrated clearance studies are accurate for determining GFR but require special facilities for handling and measuring samples. We investigated the potential of a non-radioactive paramagnetic analog, Gadolinium (Gd)-diethylene triamine pentaacetic acid (DTPA), an approved NMR contrast agent, as a glomerular filtration marker. Instead of relying on the radioactivity of technetium, this test is based on the fact that gadolinium induces alterations in the NMR T1 relaxation times in blood and urine samples. Ninety patients underwent simultaneous determinations of GFR using 1 mCi of Tc-DTPA and 0.05 mmol/kg Gd-DTPA (Berlex Labs) IV. The patients were hydrated with oral and intravenous fluid. Following a one hour equilibrium period, three or four consecutive urine collections were obtained; plasma samples were acquired at the beginning and end of each approximately 20-minute interval. 99mTc-DTPA radioactivity was determined with a scintillation counter. T1 relaxation times were measured on a 10 MHz NMR spectrometer. These were converted to Gd-DTPA concentration by comparison with standard solutions. The Gd-DTPA derived GFR closely approximated the 99mTc-DTPA derived GFR which ranged from 15 to 147 ml/min. The equation and correlation coefficient of the regression line is y = 1.04 x -2.2, r = 0.94. Thus, Gd-DTPA is a safe, non-radioactive indicator of GFR that may provide an alternative renal clearance method for clinical studies of progressive renal disease and nephrotoxicity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1501414     DOI: 10.1038/ki.1992.230

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  7 in total

Review 1.  Measurement of renal function during drug development.

Authors:  D Craig Brater
Journal:  Br J Clin Pharmacol       Date:  2002-07       Impact factor: 4.335

Review 2.  Functional MRI of the kidney: tools for translational studies of pathophysiology of renal disease.

Authors:  Pottumarthi V Prasad
Journal:  Am J Physiol Renal Physiol       Date:  2006-05

3.  PEGylation of protein-based MRI contrast agents improves relaxivities and biocompatibilities.

Authors:  Shunyi Li; Jie Jiang; Jin Zou; Jingjuan Qiao; Shenghui Xue; Lixia Wei; Robert Long; Liya Wang; Adriana Castiblanco; Natalie White; Jen Ngo; Hui Mao; Zhi-Ren Liu; Jenny J Yang
Journal:  J Inorg Biochem       Date:  2011-11-19       Impact factor: 4.155

4.  Magnetic resonance imaging of urea transporter knockout mice shows renal pelvic abnormalities.

Authors:  Vinitha A Jacob; Calista M Harbaugh; John R Dietz; Robert A Fenton; Soo M Kim; Hayo Castrop; Jurgen Schnermann; Mark A Knepper; Chung-Lin Chou; Stasia A Anderson
Journal:  Kidney Int       Date:  2008-08-13       Impact factor: 10.612

Review 5.  Assessment of renal function with dynamic contrast-enhanced MR imaging.

Authors:  Louisa Bokacheva; Henry Rusinek; Jeff L Zhang; Vivian S Lee
Journal:  Magn Reson Imaging Clin N Am       Date:  2008-11       Impact factor: 2.266

6.  Dynamic contrast-enhanced quantitative susceptibility mapping with ultrashort echo time MRI for evaluating renal function.

Authors:  Luke Xie; Anita T Layton; Nian Wang; Peder E Z Larson; Jeff L Zhang; Vivian S Lee; Chunlei Liu; G Allan Johnson
Journal:  Am J Physiol Renal Physiol       Date:  2015-10-07

Review 7.  Dynamic Contrast Enhanced-MR CEST Urography: An Emerging Tool in the Diagnosis and Management of Upper Urinary Tract Obstruction.

Authors:  Shaowei Bo; Farzad Sedaghat; KowsalyaDevi Pavuluri; Steven P Rowe; Andrew Cohen; Max Kates; Michael T McMahon
Journal:  Tomography       Date:  2021-03-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.